{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,4]],"date-time":"2026-08-04T14:21:53Z","timestamp":1785853313348,"version":"3.56.0"},"reference-count":55,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,3,1]],"date-time":"2023-03-01T00:00:00Z","timestamp":1677628800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["31971299"],"award-info":[{"award-number":["31971299"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["GG2060190386"],"award-info":[{"award-number":["GG2060190386"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["GG2065010001"],"award-info":[{"award-number":["GG2065010001"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100009076","name":"University of Science and Technology of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100009076","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["WK2060190101"],"award-info":[{"award-number":["WK2060190101"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["WK9110000144"],"award-info":[{"award-number":["WK9110000144"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012226","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","award":["WY2060190092"],"award-info":[{"award-number":["WY2060190092"]}],"id":[{"id":"10.13039\/501100012226","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013804","name":"Fundamental Research Funds for the Central Universities","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013804","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Acta Biomaterialia"],"published-print":{"date-parts":[[2023,3]]},"DOI":"10.1016\/j.actbio.2022.12.039","type":"journal-article","created":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T02:29:37Z","timestamp":1671589777000},"page":"698-707","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Utilizing chemotherapy-induced tumor RNA nanoparticles to improve cancer chemoimmunotherapy"],"prefix":"10.1016","volume":"158","author":[{"given":"Lanhong","family":"Su","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Pan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangxia","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xingyu","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaopeng","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuanzeng","family":"Min","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.actbio.2022.12.039_bib0001","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1158\/1078-0432.CCR-14-1187","article-title":"Cancer immunotherapy: a future paradigm shift in the treatment of non-small cell lung cancer","volume":"21","author":"Anagnostou","year":"2015","journal-title":"Clin. Cancer Res."},{"issue":"3","key":"10.1016\/j.actbio.2022.12.039_bib0002","doi-asserted-by":"crossref","first-page":"60","DOI":"10.3390\/diseases10030060","article-title":"Emerging trends in immunotherapy for cancer","volume":"10","author":"Mishra","year":"2022","journal-title":"Diseases"},{"issue":"6","key":"10.1016\/j.actbio.2022.12.039_bib0003","doi-asserted-by":"crossref","first-page":"1888","DOI":"10.1016\/j.cclet.2021.01.036","article-title":"Enhancing the immune response and tumor suppression effect of antitumor vaccines adjuvanted with non-nucleotide small molecule STING agonist","volume":"32","author":"Wang","year":"2021","journal-title":"Chin. Chem. Lett."},{"issue":"1","key":"10.1016\/j.actbio.2022.12.039_bib0004","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1056\/NEJMoa1504030","article-title":"Combined nivolumab and ipilimumab or monotherapy in untreated melanoma","volume":"373","author":"Larkin","year":"2015","journal-title":"N. Engl. J. Med."},{"issue":"14","key":"10.1016\/j.actbio.2022.12.039_bib0005","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1056\/NEJMoa1712126","article-title":"Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma","volume":"378","author":"Motzer","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"21","key":"10.1016\/j.actbio.2022.12.039_bib0006","doi-asserted-by":"crossref","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","article-title":"Nivolumab plus ipilimumab in advanced non-small-cell lung cancer","volume":"381","author":"Hellmann","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"8","key":"10.1016\/j.actbio.2022.12.039_bib0007","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1016\/j.it.2018.05.001","article-title":"Defining and understanding adaptive resistance in cancer immunotherapy","volume":"39","author":"Kim","year":"2018","journal-title":"Trends Immunol."},{"issue":"5","key":"10.1016\/j.actbio.2022.12.039_bib0008","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2019.2535","article-title":"Estimation of the percentage of US patients with cancer who are eligible for and respond to checkpoint inhibitor immunotherapy drugs","volume":"2","author":"Haslam","year":"2019","journal-title":"JAMA Netw. Open"},{"issue":"1","key":"10.1016\/j.actbio.2022.12.039_bib0009","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1016\/j.immuni.2019.12.011","article-title":"Top 10 challenges in cancer immunotherapy","volume":"52","author":"Hegde","year":"2020","journal-title":"Immunity"},{"issue":"4","key":"10.1016\/j.actbio.2022.12.039_bib0010","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1038\/nrc3237","article-title":"Combining immunotherapy and targeted therapies in cancer treatment","volume":"12","author":"Vanneman","year":"2012","journal-title":"Nat. Rev. Cancer"},{"issue":"5","key":"10.1016\/j.actbio.2022.12.039_bib0011","doi-asserted-by":"crossref","first-page":"286","DOI":"10.1038\/nrc.2017.17","article-title":"Prospects for combining targeted and conventional cancer therapy with immunotherapy","volume":"17","author":"Gotwals","year":"2017","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.actbio.2022.12.039_bib0012","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1186\/s13045-021-01164-5","article-title":"Combination strategies to maximize the benefits of cancer immunotherapy","volume":"14","author":"Zhu","year":"2021","journal-title":"J. Hematol. Oncol."},{"issue":"6","key":"10.1016\/j.actbio.2022.12.039_bib0013","doi-asserted-by":"crossref","first-page":"920","DOI":"10.1038\/s41591-019-0432-4","article-title":"Immune induction strategies in metastatic triple-negative breast cancer to enhance the sensitivity to PD-1 blockade: the TONIC trial","volume":"25","author":"Voorwerk","year":"2019","journal-title":"Nat. Med."},{"issue":"7","key":"10.1016\/j.actbio.2022.12.039_bib0014","doi-asserted-by":"crossref","DOI":"10.1038\/d41573-022-00030-4","article-title":"Challenges and opportunities in the PD1\/PDL1 inhibitor clinical trial landscape","volume":"21","author":"Upadhaya","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.actbio.2022.12.039_bib0015","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.canlet.2018.01.050","article-title":"Immunogenic chemotherapy: dose and schedule dependence and combination with immunotherapy","volume":"419","author":"Wu","year":"2018","journal-title":"Cancer Lett."},{"issue":"41","key":"10.1016\/j.actbio.2022.12.039_bib0016","doi-asserted-by":"crossref","first-page":"17218","DOI":"10.1039\/D1NR05512G","article-title":"Chemotherapeutic drug-induced immunogenic cell death for nanomedicine-based cancer chemo-immunotherapy","volume":"13","author":"Jiang","year":"2021","journal-title":"Nanoscale"},{"issue":"12","key":"10.1016\/j.actbio.2022.12.039_bib0017","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1038\/s41571-020-0413-z","article-title":"Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors","volume":"17","author":"Galluzzi","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.actbio.2022.12.039_bib0018","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1186\/s13058-015-0669-x","article-title":"Lymphocyte depletion and repopulation after chemotherapy for primary breast cancer","volume":"18","author":"Verma","year":"2016","journal-title":"Breast Cancer Res."},{"issue":"1","key":"10.1016\/j.actbio.2022.12.039_bib0019","doi-asserted-by":"crossref","first-page":"4951","DOI":"10.1038\/s41467-020-18745-6","article-title":"Targeted scavenging of extracellular ROS relieves suppressive immunogenic cell death","volume":"11","author":"Deng","year":"2020","journal-title":"Nat. Commun."},{"issue":"705","key":"10.1016\/j.actbio.2022.12.039_bib0020","doi-asserted-by":"crossref","first-page":"eabc4764","DOI":"10.1126\/scisignal.abc4764","article-title":"The injury response to DNA damage in live tumor cells promotes antitumor immunity","volume":"14","author":"Sriram","year":"2021","journal-title":"Sci. Signal."},{"issue":"6","key":"10.1016\/j.actbio.2022.12.039_bib0021","doi-asserted-by":"crossref","first-page":"1353","DOI":"10.1158\/2159-8290.CD-20-1312","article-title":"Paradigms on immunotherapy combinations with chemotherapy","volume":"11","author":"Salas-Benito","year":"2021","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.actbio.2022.12.039_bib0022","doi-asserted-by":"crossref","first-page":"5797","DOI":"10.1038\/s41467-022-33598-x","article-title":"Chemotherapy-induced complement signaling modulates immunosuppression and metastatic relapse in breast cancer","volume":"13","author":"Monteran","year":"2022","journal-title":"Nat. Commun."},{"issue":"11","key":"10.1016\/j.actbio.2022.12.039_bib0023","doi-asserted-by":"crossref","first-page":"1874","DOI":"10.1166\/mex.2021.2108","article-title":"Mechanism of long-chain non-coding RNA hypoxia-inducible factor 1a-antisense RNA 1 regulating chemotherapy resistance of retinoblastoma by inhibiting hypoxia- inducible factor-a","volume":"11","author":"Gu","year":"2021","journal-title":"Mater. Express"},{"issue":"4","key":"10.1016\/j.actbio.2022.12.039_bib0024","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1038\/nrd.2017.243","article-title":"mRNA vaccines - a new era in vaccinology","volume":"17","author":"Pardi","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"issue":"10","key":"10.1016\/j.actbio.2022.12.039_bib0025","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1038\/nrd4278","article-title":"mRNA-based therapeutics\u2013developing a new class of drugs","volume":"13","author":"Sahin","year":"2014","journal-title":"Nat. Rev. Drug Discov."},{"issue":"10","key":"10.1016\/j.actbio.2022.12.039_bib0026","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/nrd.2018.132","article-title":"An RNA toolbox for cancer immunotherapy","volume":"17","author":"Pastor","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.actbio.2022.12.039_bib0027","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1186\/s12943-021-01335-5","article-title":"mRNA vaccine for cancer immunotherapy","volume":"20","author":"Miao","year":"2021","journal-title":"Mol. Cancer"},{"issue":"3","key":"10.1016\/j.actbio.2022.12.039_bib0028","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.molmed.2019.10.002","article-title":"Tailoring mRNA vaccine to balance innate\/adaptive immune response","volume":"26","author":"Linares-Fernandez","year":"2020","journal-title":"Trends Mol. Med."},{"key":"10.1016\/j.actbio.2022.12.039_bib0029","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.923647","article-title":"Potentialities and challenges of mRNA vaccine in cancer immunotherapy","volume":"13","author":"Duan","year":"2022","journal-title":"Front. Immunol."},{"issue":"1","key":"10.1016\/j.actbio.2022.12.039_bib0030","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1186\/s12943-021-01310-0","article-title":"Identification of tumor antigens and immune subtypes of pancreatic adenocarcinoma for mRNA vaccine development","volume":"20","author":"Huang","year":"2021","journal-title":"Mol. Cancer"},{"issue":"4","key":"10.1016\/j.actbio.2022.12.039_bib0031","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1046\/j.1523-1747.2000.00929.x","article-title":"Induction of anti-tumor immunity with epidermal cells pulsed with tumor-derived RNA or intradermal administration of RNA","volume":"114","author":"Granstein","year":"2000","journal-title":"J. Invest. Dermatol."},{"key":"10.1016\/j.actbio.2022.12.039_bib0032","doi-asserted-by":"crossref","first-page":"3492","DOI":"10.1038\/ncomms4492","article-title":"Blockade of TLR3 protects mice from lethal radiation-induced gastrointestinal syndrome","volume":"5","author":"Takemura","year":"2014","journal-title":"Nat. Commun."},{"issue":"11","key":"10.1016\/j.actbio.2022.12.039_bib0033","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1084\/jem.20081370","article-title":"TLR3 is an endogenous sensor of tissue necrosis during acute inflammatory events","volume":"205","author":"Cavassani","year":"2008","journal-title":"J. Exp. Med."},{"issue":"12","key":"10.1016\/j.actbio.2022.12.039_bib0034","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1038\/nrc3380","article-title":"Immunogenic cell death and DAMPs in cancer therapy","volume":"12","author":"Krysko","year":"2012","journal-title":"Nat. Rev. Cancer"},{"issue":"2","key":"10.1016\/j.actbio.2022.12.039_bib0035","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1084\/jem.184.2.465","article-title":"Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo","volume":"184","author":"Boczkowski","year":"1996","journal-title":"J. Exp. Med."},{"issue":"3","key":"10.1016\/j.actbio.2022.12.039_bib0036","doi-asserted-by":"crossref","first-page":"977","DOI":"10.1182\/blood-2002-04-1273","article-title":"Induction of myeloma-specific cytotoxic T cells using dendritic cells transfected with tumor-derived RNA","volume":"101","author":"Milazzo","year":"2003","journal-title":"Blood"},{"key":"10.1016\/j.actbio.2022.12.039_bib0037","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1186\/1479-5876-6-21","article-title":"Whole tumor antigen vaccination using dendritic cells: comparison of RNA electroporation and pulsing with UV-irradiated tumor cells","volume":"6","author":"Benencia","year":"2008","journal-title":"J. Transl. Med."},{"issue":"7","key":"10.1016\/j.actbio.2022.12.039_bib0038","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1084\/jem.186.7.1177","article-title":"Bone marrow-generated dendritic cells pulsed with tumor extracts or tumor RNA induce antitumor immunity against central nervous system tumors","volume":"186","author":"Ashley","year":"1997","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.actbio.2022.12.039_bib0039","doi-asserted-by":"crossref","first-page":"286","DOI":"10.3389\/fphar.2015.00286","article-title":"Advances and challenges of liposome assisted drug delivery","volume":"6","author":"Sercombe","year":"2015","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.actbio.2022.12.039_bib0040","doi-asserted-by":"crossref","DOI":"10.1016\/j.cellimm.2020.104143","article-title":"Intranasal delivery of cationic liposome-protamine complex mRNA vaccine elicits effective anti-tumor immunity","volume":"354","author":"Mai","year":"2020","journal-title":"Cell Immunol."},{"issue":"6","key":"10.1016\/j.actbio.2022.12.039_bib0041","doi-asserted-by":"crossref","first-page":"877","DOI":"10.3390\/pharmaceutics13060877","article-title":"Protamine-based strategies for RNA transfection","volume":"13","author":"Jarzebska","year":"2021","journal-title":"Pharmaceutics"},{"issue":"7","key":"10.1016\/j.actbio.2022.12.039_bib0042","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1016\/j.ctrv.2006.07.001","article-title":"Irinotecan in the treatment of colorectal cancer","volume":"32","author":"Fuchs","year":"2006","journal-title":"Cancer Treat Rev."},{"key":"10.1016\/j.actbio.2022.12.039_bib0043","doi-asserted-by":"crossref","DOI":"10.1016\/j.phrs.2019.104398","article-title":"Irinotecan: 25 years of cancer treatment","volume":"148","author":"Bailly","year":"2019","journal-title":"Pharmacol. Res."},{"issue":"1","key":"10.1016\/j.actbio.2022.12.039_bib0044","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1007\/s00262-010-0926-x","article-title":"Topoisomerase inhibitors modulate expression of melanocytic antigens and enhance T cell recognition of tumor cells","volume":"60","author":"Haggerty","year":"2011","journal-title":"Cancer Immunol. Immunother."},{"issue":"3","key":"10.1016\/j.actbio.2022.12.039_bib0045","doi-asserted-by":"crossref","first-page":"301","DOI":"10.3109\/1547691X.2012.693547","article-title":"Combined treatment of human colorectal tumor cell lines with chemotherapeutic agents and ionizing irradiation can in vitro induce tumor cell death forms with immunogenic potential","volume":"9","author":"Frey","year":"2012","journal-title":"J. Immunotoxicol."},{"issue":"7","key":"10.1016\/j.actbio.2022.12.039_bib0046","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1093\/jnci\/djx257","article-title":"The effect of topoisomerase I inhibitors on the efficacy of T-cell-based cancer immunotherapy","volume":"110","author":"McKenzie","year":"2018","journal-title":"J. Natl. Cancer Inst."},{"issue":"6","key":"10.1016\/j.actbio.2022.12.039_bib0047","doi-asserted-by":"crossref","DOI":"10.1002\/advs.202002147","article-title":"Combination chemo-immunotherapy for pancreatic cancer using the immunogenic effects of an irinotecan silicasome nanocarrier plus anti-PD-1","volume":"8","author":"Liu","year":"2021","journal-title":"Adv. Sci."},{"issue":"11","key":"10.1016\/j.actbio.2022.12.039_bib0048","doi-asserted-by":"crossref","first-page":"3764","DOI":"10.1021\/ja111312h","article-title":"Small-molecule inhibitors of the TLR3\/dsRNA complex","volume":"133","author":"Cheng","year":"2011","journal-title":"J. Am. Chem. Soc."},{"issue":"9","key":"10.1016\/j.actbio.2022.12.039_bib0049","doi-asserted-by":"crossref","first-page":"1516","DOI":"10.1038\/s41401-020-00570-8","article-title":"Anti-PD-L1 mediating tumor-targeted codelivery of liposomal irinotecan\/JQ1 for chemo-immunotherapy","volume":"42","author":"He","year":"2021","journal-title":"Acta Pharmacol. Sin."},{"issue":"12","key":"10.1016\/j.actbio.2022.12.039_bib0050","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.it.2016.09.006","article-title":"Dendritic cells and cancer immunity","volume":"37","author":"Gardner","year":"2016","journal-title":"Trends Immunol."},{"issue":"48","key":"10.1016\/j.actbio.2022.12.039_bib0051","doi-asserted-by":"crossref","first-page":"8154","DOI":"10.1002\/adma.201402996","article-title":"Immunological responses triggered by photothermal therapy with carbon nanotubes in combination with anti-CTLA-4 therapy to inhibit cancer metastasis","volume":"26","author":"Wang","year":"2014","journal-title":"Adv. Mater."},{"issue":"5","key":"10.1016\/j.actbio.2022.12.039_bib0052","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1002\/eji.200425656","article-title":"Toll-like receptor-dependent activation of several human blood cell types by protamine-condensed mRNA","volume":"35","author":"Scheel","year":"2005","journal-title":"Eur. J. Immunol."},{"issue":"1","key":"10.1016\/j.actbio.2022.12.039_bib0053","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ymthe.2017.10.020","article-title":"Combination immunotherapy of MUC1 mRNA nano-vaccine and CTLA-4 blockade effectively inhibits growth of triple negative breast cancer","volume":"26","author":"Liu","year":"2018","journal-title":"Mol. Ther."},{"key":"10.1016\/j.actbio.2022.12.039_bib0054","series-title":"Macrophage Membrane-Camouflaged shRNA and Doxorubicin: A pH-Dependent Release System for Melanoma Chemo-Immunotherapy","author":"Yang","year":"2022"},{"issue":"2","key":"10.1016\/j.actbio.2022.12.039_bib0055","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1111\/cei.13060","article-title":"In-vitro effect of pembrolizumab on different T regulatory cell subsets","volume":"191","author":"Toor","year":"2018","journal-title":"Clin. Exp. Immunol."}],"container-title":["Acta Biomaterialia"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S174270612200842X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S174270612200842X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,28]],"date-time":"2025-10-28T18:08:08Z","timestamp":1761674888000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S174270612200842X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3]]},"references-count":55,"alternative-id":["S174270612200842X"],"URL":"https:\/\/doi.org\/10.1016\/j.actbio.2022.12.039","relation":{},"ISSN":["1742-7061"],"issn-type":[{"value":"1742-7061","type":"print"}],"subject":[],"published":{"date-parts":[[2023,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Utilizing chemotherapy-induced tumor RNA nanoparticles to improve cancer chemoimmunotherapy","name":"articletitle","label":"Article Title"},{"value":"Acta Biomaterialia","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.actbio.2022.12.039","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}